← Leaderboards
Cohava Gelber
Serpin Pharma, Llc
$1,227,402
Attributed
$2,230,328
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $838.7K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,230,328 · 4
By mechanism
R44$1,464,067 · 1
R43$541,786 · 2
N43$224,475 · 1
Top collaborators
- Dana E. Austin2 shared
- Wendy Marie Campana1 shared
- Soren Mogelsvang1 shared
Others in their field
Top investigators on “Pain”
- Emer Leahy · Psychogenics, Inc.$49,781,254
- Lynn Larson Debar · Kaiser Foundation Research Institute$37,527,482
- J Richard Landis · University Of Pennsylvania$34,799,488
- Clifford J Woolf · Boston Children'S Hospital$30,992,766
- Emeran A Mayer · University Of California Los Angeles$29,229,798
- Pamela Susan Douglas · Duke University$28,862,172
Research focus
PainPlasmaIn VivoPaclitaxelPharmaceutical PreparationsChemotherapy-Induced Peripheral NeuropathyImpairmentIn VitroMouse ModelNeuropathyChemotherapyPeripheral Nervous System DiseasesAnalgesicsAffectChronic PainDoseBiological AvailabilityInflammationAnti-Inflammatory AgentsMda Mb 231AgonistNerve DamageCancer SurvivorPrevent
Grant awards (5)
A Novel LRP1 Agonist, SP16, as a Therapeutic Treatment in Preventing Chemotherapy-Induced Peripheral Neuropathy$625,359
R44 · FY2025 · CA · contact PI
A Novel LRP1 Agonist, SP16, as a Therapeutic Treatment in Preventing Chemotherapy-Induced Peripheral Neuropathy$838,708
R44 · FY2024 · CA · contact PI
Pre-clinical validation of Phase II peptide LRP-1 agonist to treat and prevent chemotherapy induced peripheral neuropathy.$398,816
R43 · FY2022 · CA · contact PI
MONOCLONAL ANTIBODY TARGETING CANCER STEM CELLS$224,475
N43 · FY2014 · CA · contact PI
Development of new anti-inflammatory peptides for treatment of type I diabetes$142,970
R43 · FY2013 · DK